Lipid-lowering effects of curcumin in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial

Phytotherapy Research

Volumn 28, Issue 12, 2014, Pages 1770-1777

  Yang, Yi Sun ^a,b   Su, Ying Fang ^a,b   Yang, Hui Wen ^a,b   Lee, Yu Hsien ^a,b   Chou, Janet I ^c   Ueng, Kwo Chang ^a,b,d  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL TAICHUNG UNIVERSITY OF EDUCATION   (Taiwan)

Author keywords

Curcumin; Lipid lowering effect; Metabolic syndrome

Indexed keywords

CURCUMIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NAUSEA; PATIENT COMPLIANCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84917730756     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5197     Document Type: Article

References (41)

1. Alwi I, Santoso T, Suyono S, et al. 2008. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 40: 201-210.
2. Ammon HP, Wahl MA. 1991. Pharmacology of Curcuma longa. Planta Med 57: 1-7.
3. Baum L, Cheung SK, Mok VC, et al. 2007. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 56: 509-514.
4. Chandran B, Goel A. 2012. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 26: 1719-1725.
5. Cheng AL, Hsu CH, Lin JK, et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent in patients with high risk or pre malignant lesion. Anticancer Res 21: 2895-2900.
6. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. 2012a. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35: 2121-2127.
7. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. 2012b. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35: 2121-2127.
8. Di Lorenzo C, Dell'Agli M, Badea M, et al. 2013. Plant food supplements with anti-inflammatory properties: a systematic review (II). Crit Rev Food Sci Nutr 53: 507-516.
9. DiSilvestro RA, Joseph E, Zhao S, Bomser J. 2012. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11: 79.
10. Dulbecco P, Savarino V. 2013. Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol 19: 9256-9270.
11. Feng D, Ohlsson L, Duan RD. 2010. Curcumin inhibits cholesterol uptake in Caco-2 cells by down-regulation of NPC1L1 expression. Lipids Health Dis 9: 40.
12. Gupta SC, Patchva S, Koh W, Aggarwal BB. 2012. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39: 283-299.
13. Halverstadt A, Phares DA, Wilund KR, Goldberg AP, Hagberg JM. 2007. Endurance exercise training raises high-density lipoprotein cholesterol and lowers small low-density lipoprotein and very low density lipoprotein independent of body fat phenotypes in older men and women. Metabolism 56: 444-450.
14. Hu GX, Lin H, Lian QQ, et al. 2013. Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats. PLoS One 83: e49976.
15. Ireson C, Orr S, Jones DJ, et al. 2001. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61: 1058-1064.
16. Irving GR, Karmokar A, Berry DP, Brown K, Steward WP. 2011. Curcumin: the potential for efficacy in gastrointestinal diseases. Best Pract Res Clin Gastroenterol 25: 519-534.
17. Ji JL, Huang XF, Zhu HL. 2012. Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med Chem 12: 210-218.
18. Kelley GA, Kelley KS. 2009. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med 481: 9-19.
19. Kim M, Kim Y. 2010. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract 4: 191-195.
20. Madaric A, Kadrabova J, Krajcovicova-Kudlackova M, et al. 2013. The effect of bioactive complex of quercetin, selenium, catechins and curcumin on cardiovascular risk markers in healthy population after a two month consumption. Bratisl Lek Listy 114: 84-87.
21. Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27: 374-379.
22. Nguyen HL, Goldberg RJ, Gore JM, et al. 2010. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. Coron Artery Dis 21: 336-344.
23. Pan MH, Huang TM, Lin JK. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27: 486-494.
24. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. 2014. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebocontrolled trial. Phytother Res [Epub ahead of print]
25. Pungcharoenkul K, Thongnopnua P. 2011. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res 25: 1721-1726.
26. Ramirez-Bosca A, Soler A, Carrion MA, et al. 2000. An hydroalcoholic extract of Curcuma longa lowers the apo B/ apo A ratio. Implications for atherogenesis prevention. Mech Ageing Dev 119: 41-47.
27. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N. 2008. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-146.
28. Sahebkar A. 2013a. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr S0261-5614(13)00250-1.
29. Sahebkar A. 2013b. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39: 197-208.
30. Sahebkar A. 2014a. Are curcuminoids effective C-reactive proteinlowering agents in clinical practice? Evidence from a metaanalysis. Phytother Res 28: 633-642.
31. Sahebkar A. 2014b. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 11: 123.
32. Sahebkar A. 2014c. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin Pharmacol Toxicol. [Epub ahead of print] 2014; 114: 437-443.
33. Sahebkar A, Mohammadi A, Atabati A, et al. 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27: 1883-1888.
34. Sanmukhani J, Satodia V, Trivedi J, et al. 2014. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 28: 579-585.
35. Shehzad A, Ha T, Subhan F, Lee YS. 2011. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesityrelated metabolic diseases. Eur J Nutr 50: 151-161.
36. Soni KB, Kuttan R. 1992. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36: 273-275.
37. Srinivasan M. 1972. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26: 269-270.
38. Turnbull F, Arima H, Heeley E, et al. 2011. Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study. Eur J Cardiovasc Prev Rehabil 18: 498-503.
39. Wang YJ, Pan MH, Cheng AL, et al. 1997. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15: 1867-1876.
40. Wickenberg J, Ingemansson SL, Hlebowicz J. 2010. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J 9: 43.
41. Zingg JM, Hasan ST, Meydani M. 2013. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 39: 101-121.